
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TdT CRISPR/Cas9 KO Plasmid (h) | sc-406822 | 20 µg | $397.00 |
DNTT encodes terminal deoxynucleotidyl transferase (TdT), a specialized DNA polymerase that adds non-templated nucleotides to V(D)J recombination intermediates during lymphocyte development. By increasing junctional diversity at immunoglobulin and T cell receptor loci, TdT shapes antigen receptor repertoires and contributes to adaptive immune specificity. TdT activity is tightly linked to DNA double-strand break repair processes and end-joining events occurring at recombination signal sequences. Aberrant DNTT expression is widely used as a marker of immature lymphoid states and is frequently studied in the context of leukemogenesis, genomic instability, and lineage specification.
TdT CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the DNTT gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the DNTT together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the DNTT open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish TdT protein expression.
This CRISPR knockout system enables efficient generation of DNTT-deficient cell models for investigation of TdT signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.